BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J Drug Target. 2006;14:632-645. [PMID: 17090399 DOI: 10.1080/10611860600888850] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. European Journal of Pharmaceutics and Biopharmaceutics 2009;71:161-72. [DOI: 10.1016/j.ejpb.2008.09.003] [Cited by in Crossref: 288] [Cited by in F6Publishing: 250] [Article Influence: 22.2] [Reference Citation Analysis]
2 Kishore N, Raja MD, Kumar CS, Dhanalekshmi U, Srinivasan R. Lipid carriers for delivery of celecoxib: In vitro, in vivo assessment of nanomedicine in rheumatoid arthritis: Lipid carriers for delivery of celecoxib. Eur J Lipid Sci Technol 2016;118:949-58. [DOI: 10.1002/ejlt.201400658] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Patel V, Lalani R, Bardoliwala D, Ghosh S, Misra A. Lipid-Based Oral Formulation Strategies for Lipophilic Drugs. AAPS PharmSciTech 2018;19:3609-30. [DOI: 10.1208/s12249-018-1188-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
4 Venishetty VK, Chede R, Komuravelli R, Adepu L, Sistla R, Diwan PV. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration. Colloids and Surfaces B: Biointerfaces 2012;95:1-9. [DOI: 10.1016/j.colsurfb.2012.01.001] [Cited by in Crossref: 96] [Cited by in F6Publishing: 86] [Article Influence: 9.6] [Reference Citation Analysis]
5 Souto EB, Müller RH. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb Exp Pharmacol 2010;:115-41. [PMID: 20217528 DOI: 10.1007/978-3-642-00477-3_4] [Cited by in Crossref: 114] [Cited by in F6Publishing: 101] [Article Influence: 9.5] [Reference Citation Analysis]
6 Poovaiah N, Davoudi Z, Peng H, Schlichtmann B, Mallapragada S, Narasimhan B, Wang Q. Treatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers. Nanoscale 2018;10:16962-83. [DOI: 10.1039/c8nr04073g] [Cited by in Crossref: 59] [Cited by in F6Publishing: 18] [Article Influence: 14.8] [Reference Citation Analysis]
7 Gasco MR, Priano L, Zara GP. Solid lipid nanoparticles and microemulsions for drug delivery. Nanoneuroscience and Nanoneuropharmacology. Elsevier; 2009. pp. 181-92. [DOI: 10.1016/s0079-6123(08)80010-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
8 Ganesan P, Narayanasamy D. Lipid nanoparticles: Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustainable Chemistry and Pharmacy 2017;6:37-56. [DOI: 10.1016/j.scp.2017.07.002] [Cited by in Crossref: 121] [Cited by in F6Publishing: 44] [Article Influence: 24.2] [Reference Citation Analysis]
9 Cooper DL, Conder CM, Harirforoosh S. Nanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity. Expert Opin Drug Deliv 2014;11:1661-80. [PMID: 25054316 DOI: 10.1517/17425247.2014.938046] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
10 Beduneau A, Ma Z, Grotepas CB, Kabanov A, Rabinow BE, Gong N, Mosley RL, Dou H, Boska MD, Gendelman HE. Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One 2009;4:e4343. [PMID: 19183814 DOI: 10.1371/journal.pone.0004343] [Cited by in Crossref: 99] [Cited by in F6Publishing: 94] [Article Influence: 7.6] [Reference Citation Analysis]
11 Souto EB, Doktorovová S. Chapter 6 - Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery. Methods Enzymol 2009;464:105-29. [PMID: 19903552 DOI: 10.1016/S0076-6879(09)64006-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
12 Kumar Gaur P, Mishra S, Purohit S. Nanovesicles of nitrendipine with lipid complex for transdermal delivery: pharmacokinetic and pharmacodynamic studies. Artif Cells Nanomed Biotechnol 2016;44:1684-93. [PMID: 26375758 DOI: 10.3109/21691401.2015.1080170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Fiandra L, Capetti A, Sorrentino L, Corsi F. Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art. J Neuroimmune Pharmacol 2017;12:17-30. [PMID: 27832401 DOI: 10.1007/s11481-016-9716-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
14 Harms M, Müller-goymann C. Solid lipid nanoparticles for drug delivery. Journal of Drug Delivery Science and Technology 2011;21:89-99. [DOI: 10.1016/s1773-2247(11)50008-5] [Cited by in Crossref: 31] [Article Influence: 2.8] [Reference Citation Analysis]
15 Claudio P, Reatul K, Brigitte E, Geraldine P. Drug-delivery nanocarriers to cross the blood–brain barrier. Nanobiomaterials in Drug Delivery. Elsevier; 2016. pp. 333-70. [DOI: 10.1016/b978-0-323-42866-8.00010-1] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Sivadasan D, Sultan MH, Madkhali O, Almoshari Y, Thangavel N. Polymeric Lipid Hybrid Nanoparticles (PLNs) as Emerging Drug Delivery Platform-A Comprehensive Review of Their Properties, Preparation Methods, and Therapeutic Applications. Pharmaceutics 2021;13:1291. [PMID: 34452251 DOI: 10.3390/pharmaceutics13081291] [Reference Citation Analysis]
17 Mohammadi P, Mahjub R, Mohammadi M, Derakhshandeh K, Ghaleiha A, Mahboobian MM. Pharmacokinetics and brain distribution studies of perphenazine-loaded solid lipid nanoparticles. Drug Dev Ind Pharm 2021;47:146-52. [PMID: 33307865 DOI: 10.1080/03639045.2020.1862172] [Reference Citation Analysis]
18 Craparo EF, Bondì ML, Pitarresi G, Cavallaro G. Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neurosci Ther 2011;17:670-7. [PMID: 20950327 DOI: 10.1111/j.1755-5949.2010.00199.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
19 Gastaldi L, Battaglia L, Peira E, Chirio D, Muntoni E, Solazzi I, Gallarate M, Dosio F. Solid lipid nanoparticles as vehicles of drugs to the brain: Current state of the art. European Journal of Pharmaceutics and Biopharmaceutics 2014;87:433-44. [DOI: 10.1016/j.ejpb.2014.05.004] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 12.9] [Reference Citation Analysis]
20 Hulou MM, Cho C, Chiocca EA, Bjerkvig R. Experimental therapies. Gliomas. Elsevier; 2016. pp. 183-97. [DOI: 10.1016/b978-0-12-802997-8.00011-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
21 Yassemi A, Kashanian S, Zhaleh H. Folic acid receptor-targeted solid lipid nanoparticles to enhance cytotoxicity of letrozole through induction of caspase-3 dependent-apoptosis for breast cancer treatment. Pharmaceutical Development and Technology 2020;25:397-407. [DOI: 10.1080/10837450.2019.1703739] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
22 Daneshmand S, Golmohammadzadeh S, Jaafari MR, Movaffagh J, Rezaee M, Sahebkar A, Malaekeh-Nikouei B. Encapsulation challenges, the substantial issue in solid lipid nanoparticles characterization. J Cell Biochem 2018;119:4251-64. [PMID: 29243841 DOI: 10.1002/jcb.26617] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
23 Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, Porter CJ. Strategies to address low drug solubility in discovery and development. Pharmacol Rev 2013;65:315-499. [PMID: 23383426 DOI: 10.1124/pr.112.005660] [Cited by in Crossref: 864] [Cited by in F6Publishing: 737] [Article Influence: 96.0] [Reference Citation Analysis]
24 Naqvi S, Panghal A, Flora SJS. Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs. Front Neurosci 2020;14:494. [PMID: 32581676 DOI: 10.3389/fnins.2020.00494] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
25 Broccatelli F, Larregieu CA, Cruciani G, Oprea TI, Benet LZ. Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev 2012;64:95-109. [PMID: 22261306 DOI: 10.1016/j.addr.2011.12.008] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
26 Balguri SP, Adelli GR, Majumdar S. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm 2016;109:224-35. [PMID: 27793755 DOI: 10.1016/j.ejpb.2016.10.015] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 13.2] [Reference Citation Analysis]
27 Lin C, Gao H, Ouyang L. Advance cardiac nanomedicine by targeting the pathophysiological characteristics of heart failure. J Control Release 2021;337:494-504. [PMID: 34358590 DOI: 10.1016/j.jconrel.2021.08.002] [Reference Citation Analysis]
28 Cao Y, Wei Z, Li M, Wang H, Yin L, Chen D, Wang Y, Chen Y, Yuan Q, Pu X, Zong L, Duan S. Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension. Curr Cancer Drug Targets 2019;19:338-47. [PMID: 29956630 DOI: 10.2174/1568009618666180629150927] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
29 Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A. Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds. Chemistry and Physics of Lipids 2012;165:438-53. [DOI: 10.1016/j.chemphyslip.2012.01.007] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
30 Rao S, Tan A, Thomas N, Prestidge CA. Perspective and potential of oral lipid-based delivery to optimize pharmacological therapies against cardiovascular diseases. J Control Release 2014;193:174-87. [PMID: 24852093 DOI: 10.1016/j.jconrel.2014.05.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
31 Gabal YM, Kamel AO, Sammour OA, Elshafeey AH. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route. Int J Pharm 2014;473:442-57. [PMID: 25062866 DOI: 10.1016/j.ijpharm.2014.07.025] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 7.9] [Reference Citation Analysis]
32 Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci 2007;32:1054-82. [PMID: 20234846 DOI: 10.1016/j.progpolymsci.2007.05.014] [Cited by in Crossref: 160] [Cited by in F6Publishing: 133] [Article Influence: 10.7] [Reference Citation Analysis]
33 Judefeind A, de Villiers MM. Drug Loading into and In Vitro Release from Nanosized Drug Delivery Systems. In: de Villiers MM, Aramwit P, Kwon GS, editors. Nanotechnology in Drug Delivery. New York: Springer; 2009. pp. 129-62. [DOI: 10.1007/978-0-387-77668-2_5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
34 Wu T, Zheng WL, Zhang SZ, Sun JH, Yuan H. Bimodal visualization of colorectal uptake of nanoparticles in dimethylhydrazine-treated mice. World J Gastroenterol 2011; 17(31): 3614-3622 [PMID: 21987608 DOI: 10.3748/wjg.v17.i31.3614] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
35 Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. Journal of Controlled Release 2008;127:97-109. [DOI: 10.1016/j.jconrel.2007.12.018] [Cited by in Crossref: 341] [Cited by in F6Publishing: 319] [Article Influence: 24.4] [Reference Citation Analysis]
36 Chen H, Mruk DD, Xia W, Bonanomi M, Silvestrini B, Cheng CY. Effective Delivery of Male Contraceptives Behind the Blood-Testis Barrier (BTB) - Lesson from Adjudin. Curr Med Chem 2016;23:701-13. [PMID: 26758796 DOI: 10.2174/0929867323666160112122724] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
37 Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R, Yang CH. Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB. Pharmaceutics 2021;13:1183. [PMID: 34452143 DOI: 10.3390/pharmaceutics13081183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
38 Fernandes C, Soni U, Patravale V. Nano-interventions for neurodegenerative disorders. Pharmacol Res 2010;62:166-78. [PMID: 20153429 DOI: 10.1016/j.phrs.2010.02.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
39 Haque S, Md S, Alam MI, Sahni JK, Ali J, Baboota S. Nanostructure-based drug delivery systems for brain targeting. Drug Dev Ind Pharm 2012;38:387-411. [PMID: 21954902 DOI: 10.3109/03639045.2011.608191] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
40 Devi R, Jain A, Hurkat P, Jain SK. Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis. Pharm Res 2015;32:3137-48. [PMID: 26198415 DOI: 10.1007/s11095-015-1677-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
41 Poovi G, Vijayakumar TM, Damodharan N. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review of the Effect of Physicochemical Formulation Factors in the Optimization Process, Different Preparation Technique, Characterization, and Toxicity. CNANO 2019;>15:436-53. [DOI: 10.2174/1573413714666180809120435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
42 Rawal SU, Patel MM. Lipid nanoparticulate systems. Lipid Nanocarriers for Drug Targeting. Elsevier; 2018. pp. 49-138. [DOI: 10.1016/b978-0-12-813687-4.00002-5] [Cited by in Crossref: 12] [Article Influence: 3.0] [Reference Citation Analysis]
43 Shah MK, Madan P, Lin S. Elucidation of intestinal absorption mechanism of carvedilol-loaded solid lipid nanoparticles using Caco-2 cell line as an in-vitro model. Pharmaceutical Development and Technology 2014;20:877-85. [DOI: 10.3109/10837450.2014.938857] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
44 Patel M, Souto EB, Singh KK. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opinion on Drug Delivery 2013;10:889-905. [DOI: 10.1517/17425247.2013.784742] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
45 Li R, Lim S, Choi H, Lee M. Solid Lipid Nanoparticles as Drug Delivery System for Water-Insoluble Drugs. Journal of Pharmaceutical Investigation 2010;40:63-73. [DOI: 10.4333/kps.2010.40.s.063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
46 Sharma M, Gupta N, Gupta S. Implications of designing clarithromycin loaded solid lipid nanoparticles on their pharmacokinetics, antibacterial activity and safety. RSC Adv 2016;6:76621-31. [DOI: 10.1039/c6ra12841f] [Cited by in Crossref: 28] [Article Influence: 4.7] [Reference Citation Analysis]
47 Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opinion on Drug Delivery 2011;8:1407-24. [DOI: 10.1517/17425247.2011.604311] [Cited by in Crossref: 169] [Cited by in F6Publishing: 147] [Article Influence: 15.4] [Reference Citation Analysis]
48 Joseph S, Bunjes H. Solid Lipid Nanoparticles for Drug Delivery. In: Douroumis D, Fahr A, editors. Drug Delivery Strategies for Poorly Water-Soluble Drugs. Oxford: John Wiley & Sons Ltd; 2013. pp. 103-49. [DOI: 10.1002/9781118444726.ch4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Poovi G, Damodharan N. Lipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs. Future Journal of Pharmaceutical Sciences 2018;4:191-205. [DOI: 10.1016/j.fjps.2018.04.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 9.3] [Reference Citation Analysis]
50 Riccardi C, Napolitano F, Montesarchio D, Sampaolo S, Melone MAB. Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases. Pharmaceutics 2021;13:1897. [PMID: 34834311 DOI: 10.3390/pharmaceutics13111897] [Reference Citation Analysis]
51 Duan Y, Dhar A, Patel C, Khimani M, Neogi S, Sharma P, Siva Kumar N, Vekariya RL. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Adv 2020;10:26777-91. [DOI: 10.1039/d0ra03491f] [Cited by in Crossref: 37] [Cited by in F6Publishing: 1] [Article Influence: 18.5] [Reference Citation Analysis]
52 Baldi A, Chaudhary M, Sethi S, Abhiav, Chandra R, Madan J. Armamentarium of nanoscaled lipid drug delivery systems customized for oral administration: In silico docking patronage, absorption phenomenon, preclinical status, clinical status and future prospects. Colloids Surf B Biointerfaces 2018;170:637-47. [PMID: 29986259 DOI: 10.1016/j.colsurfb.2018.06.061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Guan J, Zhao N, Zhai Y, Chu C, Chen H, Zhang T. Pharmacokinetic performance of the nitrendipine intravenous submicron emulsion in rats. Asian Journal of Pharmaceutical Sciences 2014;9:330-5. [DOI: 10.1016/j.ajps.2014.07.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
54 Yuan Q, Wang Y, Song R, Hou X, Yu K, Zheng J, Zhang J, Pu X, Han J, Zong L. Study on Formulation, in vivo Exposure, and Passive Targeting of Intravenous Itraconazole Nanosuspensions. Front Pharmacol 2019;10:225. [PMID: 30983994 DOI: 10.3389/fphar.2019.00225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
55 de Oliveira IF, Barbosa EJ, Peters MCC, Henostroza MAB, Yukuyama MN, Dos Santos Neto E, Löbenberg R, Bou-Chacra N. Cutting-edge advances in therapy for the posterior segment of the eye: Solid lipid nanoparticles and nanostructured lipid carriers. Int J Pharm 2020;589:119831. [PMID: 32877729 DOI: 10.1016/j.ijpharm.2020.119831] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
56 Mu H, Holm R. Solid lipid nanocarriers in drug delivery: characterization and design. Expert Opinion on Drug Delivery 2018;15:771-85. [DOI: 10.1080/17425247.2018.1504018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
57 Rawat MK, Jain A, Singh S. Studies on Binary Lipid Matrix Based Solid Lipid Nanoparticles of Repaglinide: in Vitro and in Vivo Evaluation. Journal of Pharmaceutical Sciences 2011;100:2366-78. [DOI: 10.1002/jps.22435] [Cited by in Crossref: 58] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
58 Serpe L, Canaparo R, Daperno M, Sostegni R, Martinasso G, Muntoni E, Ippolito L, Vivenza N, Pera A, Eandi M. Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. Eur J Pharm Sci. 2010;39:428-436. [PMID: 20138213 DOI: 10.1016/j.ejps.2010.01.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]